Lyra Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '26 Jun 5, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Cap	1	14	300	100	57	147
Market Cap Growth	-80.05%	-95.49%	199.99%	76.22%	-61.53%	-
Enterprise Value	15.61	3.2	218.5	2.71	11.34	74.29
PS Ratio	3.12	8.82	192.43	73.32	198.99	-
PB Ratio	-0.12	1.17	3.35	1.24	1.65	1.98
P/TBV Ratio	-0.23	1.16	2.92	1.18	1.65	1.32
EV/Sales Ratio	39.22	2.09	140.24	1.99	39.80	-
Debt / Equity Ratio	-6.17	2.61	0.24	0.01	0.01	0.02
Net Debt / Equity Ratio	-2.15	-0.53	-0.85	-1.18	-1.29	-0.97
Net Debt / EBITDA Ratio	-0.27	0.07	1.14	1.73	1.04	3.26
Net Debt / FCF Ratio	-0.27	0.09	1.18	2.20	1.52	3.15
Asset Turnover	0.01	0.01	0.01	0.02	0.00	0
Quick Ratio	2.33	3.21	5.24	6.77	2.51	15.27
Current Ratio	2.43	3.41	5.35	6.97	2.63	15.54
Return on Equity (ROE)	-906.88%	-184.99%	-73.67%	-96.08%	-79.98%	-54.09%
Return on Assets (ROA)	-64.14%	-92.18%	-53.10%	-68.30%	-64.28%	-46.37%
Return on Invested Capital (ROIC)	-168.36%	-390.34%	-482.94%	-5200.25%	-2140.61%	-1395.04%
Return on Capital Employed (ROCE)	-80.31%	-109.04%	-61.44%	-85.24%	-77.49%	-51.83%
Buyback Yield / Dilution	-19.29%	-30.74%	-64.72%	-132.83%	-51.17%	-4150.62%
Total Shareholder Return	-19.29%	-30.74%	-64.72%	-132.83%	-51.17%	-4150.62%